Scancell Holdings plc (AIM:SCLP)
London · Delayed Price · Currency is GBP · Price in GBX 9.40
-1.10 (-10.48%)
Jul 24, 2026, 5:08 PM GMT
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
20.71
Revenue / Employee
78.52K
Employees
60
Market Cap
97.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 49.66M |
| Bioventix | 12.54M |
| SkinBioTherapeutics | 5.23M |
| PureTech Health | 3.46M |
| 4basebio | 1.69M |
| Ondine Biomedical | 1.43M |
| Faron Pharmaceuticals Oy | 1.14M |
| Avacta Group | 113.00K |
Scancell Holdings News
- 2 days ago - SMALL CAP MOVERS: Scancell heads to Nasdaq as Aim's headcount falls to 612 - This is Money
- 3 days ago - AIM Market Roundup: The Mission Group, Shaires Holdings, Eleco Public - The Armchair Trader
- 4 weeks ago - Neuphoria Therapeutics (NEUP) Confirms Acquisition Talks with Scancell Holdings - GuruFocus
- 3 months ago - Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study - GlobeNewsWire
- 6 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 6 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 6 months ago - Scancell Holdings Slides: H1 2026 - Filings
- 6 months ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire